Sonal Bhatia from Pfizer: Eliquis Continues to Show Positive Results in Real World Trials

Video

It has been several years since Eliquis was approved as an oral anticoagulant but still more research is being done to show its benefits in helping patients with non-valvular atrial fibrillation.

It has been several years since Eliquis was approved as an oral anticoagulant but still more research is being done to show its benefits in helping patients with non-valvular atrial fibrillation.

Sonal Bhatia, MD, from Pfizer discussed the results of this additional research during the American College of Cardiology's annual meeting in Chicago. While Warfarin may still be the preferred treatment method for some patients Bhatia said the results of their studies showed that oral anticoagulants are a viable option for many patients as well.

Related Videos
HCPLive Five at ACC 2024 | Image Credit: HCPLive
Ankeet Bhatt, MD, MBA | Credit: X.com
Ankeet Bhatt, MD, MBA | Credit: X.com
Sara Saberi, MD | Credit: University of Michigan
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Albert Foa, MD, PhD | Credit: HCPLive
Veraprapas Kittipibul, MD | Credit: X.com
Heart Failure stock imagery. | Credit: Fotolia
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Maternal Hidradenitits Suppurativa Linked to Neonatal Mortality, Pediatric Hospitalization Risk
© 2024 MJH Life Sciences

All rights reserved.